These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20538374)

  • 21. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
    Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
    Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
    Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
    Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
    Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A
    Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
    Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
    Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
    Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
    J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory markers in AD and MCI patients with different biomarker profiles.
    Schuitemaker A; Dik MG; Veerhuis R; Scheltens P; Schoonenboom NS; Hack CE; Blankenstein MA; Jonker C
    Neurobiol Aging; 2009 Nov; 30(11):1885-9. PubMed ID: 18378357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
    Hampel H; Shen Y
    Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
    Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
    Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
    Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
    Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.